Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225] Draft guidance Technology appraisal ...

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation begins. NHS England ...

The new modifier was introduced in 2022 to allow extra weight to be given to medicines that address severe diseases. It ...

Today (1 October 2024) NICE is consulting on draft guidance that does not recommend elacestrant for treating a type of advanced breast cancer. We’ll guide you there. Get reliable scientific advice and ...

Demand for NHS Talking Therapies has reached an all-time high. The service received 1.82 million referrals in 2023/24. This is slightly higher than 2021/2022, and more than double the 884,000 received ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

The UK Government’s 2019 national action plan for AMR included the commitment to test solutions to create an incentive for companies to invest in new antimicrobials, by evaluating and paying for ...

All NICE products on people with learning disabilities. Includes any guidance and quality standards.